TABLE 2.
Efficacy Outcomes Over the First 5 Days (hours 0 to 120) of Cycle A
| Outcome | THC:CBD (n = 73), No. (%) |
Placebo (n = 74), No. (%) |
Difference (95% CI) | Relative Risk (95% CI) | P |
|---|---|---|---|---|---|
| Complete response (primary outcome)a | 17/70 (24) | 6/74 (8) | 16 (4 to 28) | 3.0 (1 to 7) | .01 |
| No use of rescue medications | 20/71 (28) | 7/74 (9) | 19 (6 to 31) | 3.0 (1 to 7) | .01 |
| No significant nausea (score <2) | 14/70 (20) | 5/74 (7) | 13 (2 to 24) | 3.0 (1 to 8) | .03 |
| Complete response and no significant nausea | 7/70 (10) | 2/74 (3) | 7 (–1 to 15) | 3.7 (1 to 17) | .10 |
| No vomiting or retching | 49/70 (70) | 43/74 (58) | 12 (–4 to 27) | 1.2 (1 to 1.5) | .14 |
| No. of vomits per day, mean | 0.2 | 0.5 | –0.3 (–0.6, –0.1) | .01 | |
| Maximum No. of vomits per day, mean | 0.6 | 1.3 | –0.7 (–1.3, –0.10) | .02 | |
| Nausea score, mean | 2.8 | 4.3 | –1.5 (–2.2 to –0.9) | <.001 | |
| Maximum nausea score, mean | 3.8 | 5.7 | –1.9 (–2.8 to –1.1) | <.001 |
Abbreviations: CBD, cannabidiol; THC, tetrahydrocannabinol.
a
No vomiting or retching and no use of rescue medications during the overall phase of cycle A (0-120 hours).